Abvc biopharma enters definitive agreement with licensing income worth $467m and royalties up to $200m

Fremont, ca, nov. 16, 2023 (globe newswire) -- via newmediawire –  abvc biopharma, inc.  (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with aibtl biopharma inc. (aibtl) for the company's cns drugs with the indications of mdd (major depressive disorder) and adhd (attention deficit hyperactivity disorder) (the "licensed products"). the agreement has the potential of licensing income worth $467m and royalties up to $200m.
ABVC Ratings Summary
ABVC Quant Ranking